Salarius Pharmaceuticals Inc Market Cap ($4.81 Million)
Market Cap & Net Worth: Salarius Pharmaceuticals Inc (SLRX)
Salarius Pharmaceuticals Inc market cap. Salarius Pharmaceuticals Inc (NASDAQ:SLRX) has a market capitalization of $4.81 Million ($4.81 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28602 globally and #5882 in its home market, demonstrating a 26.59% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Salarius Pharmaceuticals Inc's stock price $0.82 by its total outstanding shares 5862178 (5.86 Million). Also see how efficiently does Salarius Pharmaceuticals Inc generate cash for how efficiently the company converts equity into cash flow.
Salarius Pharmaceuticals Inc Market Cap History (2015–2026)
Salarius Pharmaceuticals Inc market cap history from 2015 to 2026. Data shows change from $364.92 Billion to $4.81 Million (-66.15% CAGR). Check Salarius Pharmaceuticals Inc (SLRX) share price today for real-time trading data and today's change.
Index Memberships
Salarius Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #818 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2627 of 3165 |
Weight: Salarius Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Salarius Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Salarius Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore SLRX net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
316.01x
Salarius Pharmaceuticals Inc's market cap is 316.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $154.76 Billion | $1.01 Million | -$39.49 Million | 153077.65x | N/A |
| 2017 | $102.30 Billion | $1.27 Million | -$34.43 Million | 80231.38x | N/A |
| 2018 | $9.67 Billion | $838.00K | -$21.92 Million | 11542.47x | N/A |
| 2019 | $4.43 Billion | $3.47 Million | -$6.94 Million | 1279.00x | N/A |
| 2020 | $1.07 Billion | $5.23 Million | -$7.35 Million | 203.87x | N/A |
| 2021 | $581.53 Million | $1.84 Million | -$12.77 Million | 316.01x | N/A |
Competitor Companies of SLRX by Market Capitalization
Companies near Salarius Pharmaceuticals Inc in the global market cap rankings as of November 4, 2026. Also see Salarius Pharmaceuticals Inc asset portfolio for a full breakdown of the balance sheet.
Key companies related to Salarius Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Salarius Pharmaceuticals Inc (2015–2026)
Market capitalization of Salarius Pharmaceuticals Inc from 2015 to today. Between 2015 and today, Salarius Pharmaceuticals Inc's market cap moved from $364.92 Billion to $ 4.81 Million, with a yearly change of -66.15%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.81 Million | +26.36% |
| 2025 | $3.80 Million | -64.74% |
| 2024 | $10.79 Million | -64.62% |
| 2023 | $30.48 Million | -57.52% |
| 2022 | $71.75 Million | -87.66% |
| 2021 | $581.53 Million | -45.49% |
| 2020 | $1.07 Billion | -75.93% |
| 2019 | $4.43 Billion | -54.18% |
| 2018 | $9.67 Billion | -90.54% |
| 2017 | $102.30 Billion | -33.90% |
| 2016 | $154.76 Billion | -57.59% |
| 2015 | $364.92 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Salarius Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.81 Million USD |
| MoneyControl | $4.81 Million USD |
| MarketWatch | $4.81 Million USD |
| marketcap.company | $4.81 Million USD |
| Reuters | $4.81 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Salarius Pharmaceuticals Inc
Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufac… Read more